According to the ATE Guide, it would fit with a type A therapeutic positioning, assuming that the OS variable studied for pembrolizumab does not meet statistical significance for patients with squamous histology. Conclusion and relevance Nivolumab, pembrolizumab and camrelizumab could be considered ATE. It is necessary to take into account that there is a certain degree of uncertainty in this positioning result.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.